# **Special Issue**

# Biomarkers and Rapid Microbiological Techniques for Optimizing the Diagnosis and Treatment of Patients with Sepsis

# Message from the Guest Editors

In recent years, there have been advances in the use of laboratory techniques to improve the early recognition of sepsis. Some of these involve the discovery or evaluation of biomarkers or digital signatures of sepsis in order to improve the timeliness and accuracy of diagnosis or new therapeutic targets. Rapid diagnosis and appropriate antibiotic therapies are essential and have been shown to improve survival. Despite the importance of early detection, current technologies and clinical methods are often insufficient because they lack the necessary speed, specificity or sensitivity. Given the complexity of sepsis treatment, there is a need for rapid microbiological diagnostic panels that, combined with clinical data and biomarker profiles, allow for the early optimization of empirical antibiotic treatment. Regarding the scope of this Special Issue on biomarkers and rapid microbiological diagnostic techniques, the authors should offer attractive research perspectives on the utility and impact of using different types of biomarkers or rapid microbiological identification panels in patients with sepsis.

#### **Guest Editors**

Dr. Alejandro Rodriguez

Head of Section Critical Care Department, Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain

Dr. Frederic Francesc Gómez-Bertomeu

Head of Microbiology Section, Clinical Laboratory ICS Camp de Tarragona, University Hospital of Tarragona Joan XXIII, Catalan Health Institute, Tarragona, Spain

## Deadline for manuscript submissions

closed (30 November 2023)



an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/171767

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





# **About the Journal**

## Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

#### Editor-in-Chief

#### Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

#### **Author Benefits**

#### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).